Kazuhiko Nakagawa, MD, PhD, discusses the role of EGFR tyrosine kinase inhibitors for the frontline treatment of patients with <em>EGFR</em>-positive non–small cell lung cancer.
Kazuhiko Nakagawa, MD, PhD
Articles by Kazuhiko Nakagawa, MD, PhD
